IP Verse

Apixaban Formulations

Patent No. EP3781132 (titled "Apixaban Formulations") was filed by Bristol Myers Squibb on Apr 15, 2019. The application was issued on Mar 20, 2024.

Patent Summary

A novel formulation for oral administration of apixaban that enables controlled release of the anticoagulant in food and beverages. The formulation comprises a treated core comprising a core substrate and apixaban and a carrier on the core substrate, wherein the apixaban and carrier are in a layer formed on a surface of the core substrate. The treated core is formed through a spray-layered dispersion process with apixaban in a solvent below its solubility limit. The formulation is suitable for administration through capsules, sticks, or other delivery systems that can be dispensed or dissolved in food or beverages.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STADA ARZNEIMITTELDec 19, 2024KERNEBECK

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3781132

BRISTOL MYERS SQUIBB
Application Number
EP19722333A
Filing Date
Apr 15, 2019
Status
Granted And Under Opposition
Feb 16, 2024
Publication Date
Mar 20, 2024
External Links
Slate, Register , Google Patents